Obagi Medical Products to Report Third Quarter 2009 Financial Results and Host a Conference Call on November 5, 2009

October 19, 2009 4:53 PM EDT

LONG BEACH, Calif.--(BUSINESS WIRE)-- Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that its third quarter 2009 financial results will be released after the market close on Thursday, November 5, and will be followed by an investor conference call on the same day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Investors interested in participating in the live call can dial 877-941-4776 from the U.S. International callers can dial 480-629-9762. A telephone replay will be available approximately two hours after the call concludes through Thursday, November 19, by dialing 800-406-7325 from the U.S., or 303-590-3030 for international callers, and entering confirmation code 4174669.

There also will be a simultaneous webcast available on the Investor Relations section of the Company's web site at www.obagi.com. For those unable to participate during the live broadcast, the webcast will be archived for 30 days.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm(R), 1988; Obagi-C(R) Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi(R) Professional-C (a line of highly stable vitamin C serums), 2005; Obagi(R) Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm(TM) eye treatment and Obagi CLENZIderm(R) M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm(R) M.D. Systems for normal to dry skin, June 2007; Obagi ELASTIderm(TM) Decolletage System, January 2008; and the Obagi(R) Rosaclear(TM) System for Rosacea in January 2009. Visit www.obagi.com for more information.

    Source: Obagi Medical Products, Inc.

Related Categories

Press Releases

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?